Why the study?
Does spironolactone reduce interstitial fibrosis and cardiomyocyte hypertrophy in mice with hypertensive heart disease?
Population
Mice with l-NAME induced hypertensive heart disease (n=43)
Comparison
Spironolactone combined with l-NAME for 7 weeks vs l-NAME alone (3 mg/mL in water)
Design
Preclinical, randomized
Follow-up
7 weeks
Authors
Loading...
Reduces fibrosis in hypertensive mouse model; leaves open translation to human CMR-guided therapy.
Does spironolactone reduce interstitial fibrosis and cardiomyocyte hypertrophy in mice with hypertensive heart disease?
Spironolactone attenuates interstitial fibrosis and cardiomyocyte hypertrophy in a mouse model of hypertensive heart disease, as assessed noninvasively by CMR.
Coelho‐Filho et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: